Biotechna AG is a biotechnology company focused on developing new targeted therapies based on nanotechnology. Its main activities include oncology research, siRNA-, RNA- and DNA-based products, and proprietary nanoparticle platforms for drug delivery.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of new targeted cancer therapies based on nanotechnology, siRNA and drug synergies, from basic research through preclinical studies to clinical trials.
Nanoparticle Drug Delivery
Nanoparticle platforms for delivering nucleic acids and small molecules, with stabilized payloads, targeted tumour delivery and combined transport of different active substances.
siRNA and RNA/DNA-Based Therapies
Development of RNA- and DNA-based products and siRNA approaches to silence hard-to-target mechanisms in cancer treatment.
Drug Synergies for Cancer Indications
Search for new synergies and new indications of known compounds to speed up cancer drug development and reduce associated risks and costs.
Comparisons
Biotechna AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Biotechna AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Biotechna AG has claimed this profile, we'll publish editorial articles and case studies here together.